Sotatercept · Winrevair

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Heart Failure · Phase 3 · investigational in the US

Also approved (3)
JP
  • Treatment of pulmonary arterial hypertension
Product first approved 2025PMDA
CA
  • WINREVAIR® (sotatercept) is indicated: • In combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II, III or IV (see 14 Clinical Trials).
Product first approved 2024Health Canada
EU
  • Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III and IV.
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Heart Failure
Pulmonary Arterial Hypertension
NCT04811092 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2022-03-18 – 2025-04-03 · Pulmonary Arterial Hypertension
What this study did
Phase 2 (21)
Pulmonary Arterial Hypertension
NCT07646860 · Merck Sharp & Dohme LLC
2026-09-17 – 2031-05-16 · Pulmonary Arterial Hypertension
What this study did
NCT06351345 · Bastiaan Driehuys
2025-10-27 – 2030-02-04 · Pulmonary Hypertension, Pulmonary Arterial Hypertension
What this study did
NCT07498803 · Philipps University Marburg
2026-09-01 – 2028-12-31 · Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH
What this study did
NCT07266519 · Philipps University Marburg
2026-12-01 – 2028-10 · Pulmonary Arterial Hypertension (PAH)
What this study did
NCT05587712 · Merck Sharp & Dohme LLC
2023-01-19 – 2028-09-21 · Pulmonary Arterial Hypertension
What this study did
NCT06925750 · Merck Sharp & Dohme LLC
2025-05-12 – 2028-06-16 · Pulmonary Arterial Hypertension
What this study did
NCT06664801 · Merck Sharp & Dohme LLC
2024-11-14 – 2025-11-20 · Pulmonary Arterial Hypertension
What this study did
NCT03738150 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2019-04-19 – 2022-03-22 · Pulmonary Arterial Hypertension
What this study did
NCT03496207 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2018-06-13 – 2022-03-09 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT06814145 · Merck Sharp & Dohme LLC
2025-04-16 – 2035-08-10 · Hypertension, Pulmonary
What this study did
NCT04945460 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2021-12-29 – 2026-04-09 · Hypertension, Pulmonary
What this study did
NCT01571635 · Celgene
2012-10-10 – 2022-05-24 · Beta Thalassemia Major, Beta Thalassemia Intermedia
What this study did
NCT01712308 · M.D. Anderson Cancer Center
2013-02-21 – 2022-05-24 · Anemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis
What this study did
NCT01736683 · Merck Sharp & Dohme LLC
2012-11-28 – 2018-04-30 · Anemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low to Intermediate-1 MDS, Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
What this study did
NCT01999582 · Celgene
2013-11-30 – 2016-08-31 · Anemia, Kidney Failure, Chronic
What this study did
NCT02230917 · Rebecca Silbermann
2014-10 – 2016-06 · Multiple Myeloma
What this study did
NCT01190644 · Merck Sharp & Dohme LLC
2010-06-01 – 2012-10-29 · Solid Tumors
What this study did
NCT01284348 · Merck Sharp & Dohme LLC
2011-03-25 – 2012-09-21 · Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer, Cancer of Head and Neck, Uterine Cervical Cancer
What this study did
NCT00931606 · Merck Sharp & Dohme LLC
2009-06-01 – 2010-11-18 · Chemotherapy Induced Anemia
What this study did
NCT00747123 · Celgene
2008-09-01 – 2009-08-01 · Multiple Myeloma
What this study did
Phase 1/2 (2)
Pulmonary Arterial Hypertension
NCT07357974 · University Hospital, Brest
2026-07-15 – 2028-01-01 · Pulmonary Arterial Hypertension (PAH)
What this study did
Other / comorbidity
NCT01464164 · Northwell Health
2012-01 – 2021-04-13 · Diamond Blackfan Anemia
What this study did
Phase 1 (4)
Other / comorbidity
NCT01562405 · Massachusetts General Hospital
2012-05 – 2027-12 · Multiple Myeloma
What this study did
NCT06843460 · Merck Sharp & Dohme LLC
2023-11-22 – 2024-05-21 · Healthy
What this study did
NCT00709540 · Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
2008-01 – 2008-11 · Osteoporosis
What this study did
Phase 4 (8)
Pulmonary Arterial Hypertension
NCT07140484 · University of Alberta
2025-10-06 – 2030-01-01 · Pulmonary Artery Hypertension
What this study did
NCT07938294 · Oregon Health and Science University
2026-12-01 – 2028-11-30 · Pulmonary Arterial Hypertension (PAH), Methamphetamine Use Disorder
What this study did
NCT07356778 · Kazuya Hosokawa
2025-10-07 – 2028-04-30 · Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease
What this study did
NCT07600723 · Merck Sharp & Dohme LLC
2026-10-08 – 2028-04-03 · Pulmonary Arterial Hypertension
What this study did
NCT07899905 · Merck Sharp & Dohme LLC
2026-11-30 – 2028-03-21 · Hypertension, Pulmonary
What this study did
NCT05825417 · Sheffield Teaching Hospitals NHS Foundation Trust
2023-06-14 – 2028-01 · Pulmonary Arterial Hypertension
What this study did
NCT06658522 · Amsterdam UMC, location VUmc
2025-05-14 – 2026-05-01 · Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
What this study did
NCT06409026 · Mayo Clinic
2024-07-05 – 2026-01-14 · Pulmonary Arterial Hypertension
What this study did
Early phase / not applicable (1)
Pulmonary Arterial Hypertension
NCT07700303 · University of Alberta
2026-10-30 – 2030-03-30 · Pulmonary Arterial Hypertension
What this study did

Competitive landscape

Other Activin receptor type IIA (ActRIIA) drugs

LAE102, HS235, IMC-003. Compare all 4 Activin receptor type IIA (ActRIIA) drugs

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sotatercept (Winrevair): this drugApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Riociguat (Adempas)ApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
LAE102
Phase 2(overall)
Monoclonal antibodyActivin receptor type IIA (ActRIIA)
not yet graded(overall)
No reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
IMC-003
Phase 1/2(overall)
Biologic (subtype unspecified)Activin receptor type IIA (ActRIIA)
not yet graded(overall)
No reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(18 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Winrevair (Sotatercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2026-12 · NCT01562405 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
Phase 4Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2027-08-31 · NCT07356778 · CT.gov ↗
What to watch
2028 (11)
January 2028 (2)
Phase 4Pulmonary Arterial HypertensionActive not recruiting
Est. primary completion 2028-01 · NCT05825417 · CT.gov ↗
What to watch
Phase 1/2Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-01-01 · NCT07357974 · CT.gov ↗
What to watch
March 2028 (3)
Phase 4Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-03-21 · NCT07899905 · CT.gov ↗
What to watch
Early phase / not applicablePulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-03-30 · NCT07700303 · CT.gov ↗
What to watch
Phase 2Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-03-31 · NCT07498803 · CT.gov ↗
What to watch
April 2028 (1)
Phase 4Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-04-03 · NCT07600723 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Pulmonary Arterial HypertensionActive not recruiting
Est. primary completion 2028-06-16 · NCT06925750 · CT.gov ↗
What to watch
September 2028 (2)
Phase 4Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-09-01 · NCT07938294 · CT.gov ↗
What to watch
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2028-09-21 · NCT05587712 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Pulmonary Arterial HypertensionNot yet recruiting
Est. primary completion 2028-10 · NCT07266519 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Pulmonary Arterial HypertensionActive not recruiting
Est. primary completion 2028-12-07 · NCT07218029 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 4Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2029-01-01 · NCT07140484 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2029-02-04 · NCT06351345 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Pulmonary Arterial HypertensionRecruiting
Est. primary completion 2029-05-24 · NCT07646860 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 3Heart FailureNot yet recruiting
Est. primary completion 2030-01-08 · NCT07839585 · CT.gov ↗
What to watch
2035 (1)
August 2035 (1)
Phase 2Hypertension, PulmonaryActive not recruiting
Est. primary completion 2035-08-10 · NCT06814145 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 June 2025Topline resultHYPERION Phase 3 met primary endpoint
Merck · Source ↗
25 November 2024Topline resultZENITH Phase 3 met primary endpoint at interim analysis
Merck & Co. · Source ↗